Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 7, 2005

View Archived Issues

Millennium updates pipeline progress

Locteron begins phase I study for chronic hepatitis C

Satraplatin begins phase II study in metastatic breast cancer

Tm Bioscience develops upper respiratory viral panel

GTC Biotherapeutics and LEO Pharma enter agreement for ATryn

Positive outcome for BEMA-fentanyl in comparative pharmacokinetics study

Alnylam seeks clearance for phase I study of ALN-RSV01 for RSV

Antiviral FluCide-I begins preclinical studies

DOR BioPharma to acquire Gastrotech Pharma

NF-676: novel and potent use-dependent blocker of RyR1

SL-650155 reveals effects of serotonin in models of amnesia

ACTOplus met available in U.S. for type 2 diabetes

Novel agents for the treatment of neurological disorders disclosed in recent patents

Recent patents report compounds with potential use in the treatment of respiratory disorders

New treatments for cancer covered in recent patents

In vitro effects of anti-TNF-alpha agents on apoptosis and cytotoxicity

AT-001 reported effective in the treatment of rheumatoid arthritis

AmPrbetaCD: a novel anthrax lethal toxin inhibitor

Update on the therapeutic benefits of quetiapine in psychological disorders

Acadia presents a new potent, orally available, isoform-selective RARbeta2 agonist

Phase I data on tgAAC94 in inflammatory arthritis

Clinical evidence confirms transdermal selegiline is safe in patients with major depression

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...